

# Primary Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with Sentinel node procedure (RISAS) following neoadjuvant chemotherapy (NAC): a novel surgical approach to accurately assess axillary response to neoadjuvant systemic therapy, thereby reducing future need for completion axillary lymph node dissection and subsequent morbidity

Published: 24-10-2016

Last updated: 16-04-2024

The main goal of this study is to examine the accuracy (identification rate of the MARI-node and Sentinel node, sensitivity, negative predictive value (NPV) and false-negative rate (FNR)) of the RISAS procedure compared to the current standard...

|                              |  |
|------------------------------|--|
| <b>Ethical review</b>        | Approved WMO   |
| <b>Status</b>                | Recruitment stopped                                      |
| <b>Health condition type</b> | Breast neoplasms malignant and unspecified (incl nipple) |
| <b>Study type</b>            | Interventional   |

## Summary

### ID

NL-OMON47808

### Source

ToetsingOnline

### Brief title

RISAS procedure in node positive breast cancer following NAC

## Condition

- Breast neoplasms malignant and unspecified (incl nipple)
- Breast therapeutic procedures

### Synonym

lymph node metastasis

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Erasmus MC, Universitair Medisch Centrum Rotterdam

**Source(s) of monetary or material Support:** KWF/Alpe d'Huzes foundation

## Intervention

**Keyword:** Axillary lymph nodes, Breast cancer, Complete response, Neoadjuvant chemotherapy

## Outcome measures

### Primary outcome

The main goal of this study is to examine the accuracy (identification rate, sensitivity, NPV and FNR) of the RISAS procedure to identify axillary pCR, compared to the current axillary surgical procedure ALND. The pathologic examination of the ALND is the gold standard for nodal involvement and staging.

If the RISAS procedure is accurate in the evaluation of axillary pCR, this can result in reducing an ALND in these patients, thereby reducing the risk of developing potential morbidity of axillary surgery.

### Secondary outcome

The secondary objective of this study is to examine the accuracy (identification rate, sensitivity, NPV and FNR) of both techniques used in

RISAS separately (i.e. SLNB and MARI), compared to ALND. Again, the pathologic examination of the ALND will be regarded as the gold standard for nodal involvement and staging.

Subgroup analyses might demonstrate that the use of a single technique is sufficiently accurate to identify axillary pCR in certain subgroups, indicating these patients only require either SLNB or MARI.

## Study description

### Background summary

Chemotherapy in clinically node positive breast cancer patients is increasingly administered in a neoadjuvant setting. The standard treatment regimen in these cases is then: neoadjuvant chemotherapy (NAC) followed by breast surgery and an axillary lymph node dissection (ALND). NAC results in axillary pathologic complete response (pCR) in 1 out of 3 patients, indicating a complete absence of axillary metastases after completion of NAC. In such events, ALND can be regarded as overtreatment that creates unnecessary morbidity. Less invasive axillary surgery which can accurately assess axillary pCR is therefore preferred over standard ALND in all patients. In case of detection of remaining axillary lymph node metastases by this less invasive axillary surgical procedure, completion axillary treatment is standard of care.

The novel RISAS procedure is introduced as a possible less invasive axillary staging procedure. RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.

### Study objective

The main goal of this study is to examine the accuracy (identification rate of the MARI-node and Sentinel node, sensitivity, negative predictive value (NPV) and false-negative rate (FNR)) of the RISAS procedure compared to the current standard axillary lymph node dissection in clinically node positive breast cancer patients, treated with NAC.

### Study design

The study is designed as an open-single arm multicenter intervention study. In this study 248 patients will be included during a 2 year period. Patients will be recruited in:

- Academic Breast Cancer Centre, Erasmus MC, Rotterdam
- Amphia Hospital, Breda
- Maastricht University Medical Centre, Maastricht
- University Medical Centre Utrecht, Utrecht

For this study, it is required that each participating hospital is already using I-125 seed placement to localize the primary tumor in breast cancer patients. As a consequence, all participating surgical oncologists are experienced with the use of I-125 seeds.

a) The RISAS-procedure consists of: insertion of an I-125 seed in a positive axillary lymph node, prior to the start of NAC. The I-125 seed will be placed simultaneously with the standard I-125 localisation procedure of the breast tumor which precludes extra visits. In case of several suspicious nodes on ultrasound, confirmed by pathology, the I-125 seed will be placed in the most suspicious node.

b) sentinel lymph node biopsy (SLNB): this procedure is a standard technique in clinically node negative breast cancer.

During definitive axillary surgery, the ALND is preceded by both selective excisions of the MARI-node as well as the dual tracer sentinel node(s). It may occur that both procedures converge in the same axillary lymph node.

## **Intervention**

Prior to start of NAC, an I-125 seed will be placed in the pathologically confirmed axillary lymph node metastasis. After completion of NAC, all patients will undergo a RISAS procedure followed by ALND in a one-step surgical procedure.

## **Study burden and risks**

Patients will undergo standard workup and diagnostic procedures and treatments, according to the Dutch guideline. For this study the RISAS procedure will be performed, preceding the axillary surgery (i.e. ALND). The RISAS procedure includes:

a) insertion of an I-125 seed in a positive axillary lymph node, prior to the start of NAC. The I-125 seed will be placed simultaneously with the standard I-125 localisation procedure of the breast tumor which precludes extra visits. The I-125 seed will be placed in the lymph node which has been biopsied, i.e. node in which a metastasis was confirmed by pathology.

b) sentinel lymph node biopsy (SLNB): this procedure is a standard dual Tc-99 tracer technique in clinically node negative breast cancer.

Patients who will be participating in this study, will not benefit personally of the RISAS-procedure. However, if RISAS is proven to be an accurate method for the assessment of axillary pCR, future patients will benefit.

## Contacts

### Public

Erasmus MC, Universitair Medisch Centrum Rotterdam

Groene Hilledijk 301  
Rotterdam 3075 EA  
NL

### Scientific

Erasmus MC, Universitair Medisch Centrum Rotterdam

Groene Hilledijk 301  
Rotterdam 3075 EA  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

1. Female patient with pathologically confirmed axillary lymph node positive invasive primary breast cancer, treated with neoadjuvant chemotherapy
2. Willing and able to undergo all study procedures
3. Has personally provided written informed consent

## Exclusion criteria

1. Age < 18
2. Pregnancy or lactation
3. Contra indication for undergoing SLNB, such as allergic reaction on 99m Technetium or patent blue.
4. Recurrent breast cancer
5. Previous axillary surgery or radiotherapy, (e.g. Hodgkin disease treatment)
6. Patients with periclavicular lymph node metastases (cN3)
7. Patients with advanced breast cancer (i.e. patients with distant metastases, treated without any further surgical procedures)

## Study design

### Design

**Study type:** Interventional

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL  
Recruitment status: Recruitment stopped

Start date (anticipated): 30-03-2017

Enrollment: 248

Type: Actual

## Ethics review

Approved WMO  
Date: 24-10-2016

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO

|                    |   |
|--------------------|---|
| Date:              | 22-03-2017  |
| Application type:  | Amendment   |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO       |   |
| Date:              | 29-06-2017  |
| Application type:  | Amendment   |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO       |   |
| Date:              | 05-09-2017  |
| Application type:  | Amendment   |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO       |   |
| Date:              | 25-09-2017  |
| Application type:  | Amendment   |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO       |   |
| Date:              | 12-03-2018  |
| Application type:  | Amendment   |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO       |   |
| Date:              | 29-05-2018  |
| Application type:  | Amendment   |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO       |   |
| Date:              | 10-12-2018  |
| Application type:  | Amendment   |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO       |   |
| Date:              | 11-12-2019  |
| Application type:  | Amendment   |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam             |

(Rotterdam)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

| Register           | ID             |
|--------------------|----------------|
| ClinicalTrials.gov | NCT02800317    |
| CCMO               | NL57700.078.16 |